BioCentury
ARTICLE | Company News

R-Tech Ueno, Sucampo deal

September 14, 2015 7:00 AM UTC

Sucampo launched a tender offer to acquire R-Tech for Y33 billion ($273.9 million). R-Tech manufactures constipation drug Amitiza lubiprostone for Sucampo and Sucampo’s commercialization partners, including Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan), Mylan N.V. (NASDAQ:MYL, Canonsburg, Pa.) and Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437, Harbin, China). Its pipeline includes candidates in ophthalmology, gastroenterology, autoimmune/inflammatory disease and oncology. ...